Healthcare entity
market-trends is the sole category represented across all 1 tracked stories. Asian Society for Neuro-Oncology (ASNO) 2026 Annual Meeting is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each story carries 2 original sources on average, compared with 2.2 for the broader beat in this window.
Last mentioned: Jul 27, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
market-trends is the sole category represented across all 1 tracked stories. Asian Society for Neuro-Oncology (ASNO) 2026 Annual Meeting is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each story carries 2 original sources on average, compared with 2.2 for the broader beat in this window. The average consequence score is 6, matching the 6 beat baseline for this window. RZ-001 (Taspitimagene advec) appears in 1 tracked Healthcare story from July 27, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering RZ-001 (Taspitimagene advec). Shared-story counts are live from our verified record — not editorial picks.
Press Release Issued
Rznomics announces the presentation and key findings via PRNewswire, making the data public to investors and the biomedical community.
Interim Data Presentation at ASNO 2026
Dr. Chae-Yong Kim of Seoul National University Bundang Hospital delivers oral presentation on interim Phase 1/2a results of RZ-001 in recurrent glioblastoma, reporting safety and early efficacy signals.
Rznomics' RNA-based gene therapy RZ-001 demonstrates encouraging interim safety and efficacy in recurrent glioblastoma, with no dose-limiting toxicities and prolonged disease control in a Phase 1/2a trial presented at ASNO 2026.
Source: prnewswire.com · manilatimes.net
RZ-001 (Taspitimagene advec) is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
